Yupelri ® — Net Sales
Viatris Yupelri ® — Net Sales decreased by 11.5% to $62.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.2%, from $58.30M to $62.50M. Over 4 years (FY 2021 to FY 2025), Yupelri ® — Net Sales shows an upward trend with a 13.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market adoption or improved pricing power for the therapeutic, while a decrease may signal increased competition, patent expiration, or declining patient demand.
Detailed definition
This metric represents the total revenue generated from the sale of a specific branded respiratory therapeutic product a...
Peer comparison
Comparable to branded specialty pharmaceutical product revenue lines at other global healthcare companies, often benchmarked against similar respiratory or chronic disease therapeutic franchises.
vtrs_segment_yupelri_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $41.80M | $39.40M | $43.80M | $43.70M | $49.10M | $53.40M | $56.00M | $47.00M | $55.00M | $58.30M | $60.50M | $55.20M | $54.50M | $62.20M | $66.60M | $58.30M | $66.60M | $71.40M | $70.60M | $62.50M |
| QoQ Change | — | -5.7% | +11.2% | -0.2% | +12.4% | +8.8% | +4.9% | -16.1% | +17.0% | +6.0% | +3.8% | -8.8% | -1.3% | +14.1% | +7.1% | -12.5% | +14.2% | +7.2% | -1.1% | -11.5% |
| YoY Change | — | — | — | — | +17.5% | +35.5% | +27.9% | +7.6% | +12.0% | +9.2% | +8.0% | +17.4% | -0.9% | +6.7% | +10.1% | +5.6% | +22.2% | +14.8% | +6.0% | +7.2% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's yupelri ® — net sales?
- Viatris (VTRS) reported yupelri ® — net sales of $62.50M in Q1 2026.
- How has Viatris's yupelri ® — net sales changed year-over-year?
- Viatris's yupelri ® — net sales increased by 7.2% year-over-year, from $58.30M to $62.50M.
- What is the long-term trend for Viatris's yupelri ® — net sales?
- Over 4 years (2021 to 2025), Viatris's yupelri ® — net sales has grown at a 13.3% compound annual growth rate (CAGR), from $161.90M to $266.90M.
- What does yupelri ® — net sales mean?
- The total revenue earned from sales of the Yupelri respiratory medication.